NCT03037385: Phase1/2 Study of the Highly-selective RET Inhinitor, Pralsetinib (BLU-667), inParticpants With Thyroid Cancer, Non-Small CellLung Cancer, and Other Advanced Solid Tumors(ARROW). Here, RET is linked to thyroid gland carcinoma.